Phase I study of ABBV-383, a BCMA×CD3 bispecific antibody, in R/R myeloma
Published January 24, 2023
Views 123 | Likes 1 | Comments 0
Based on an estimated $0.7–$2 CPM, this video's 123 views translate to an estimated $0 – $0 in lifetime ad revenue.
Revenue estimate
Based on an estimated $0.7–$2CPM (revenue per 1,000 views) — a rough public estimate, not actual creator earnings, which depend on ad rates, audience geography, and monetization settings YouTube doesn't expose publicly.
Total (all-time)$0 – $0